-
Last month an article was featured in the OB/GYN Clinical Alert from the October issue of Obstetrics & Gynecology. Since the issue was rich in good material, I will go back to it to review information pertaining to one of the most common questions asked of providers"How much weight should I gain in my pregnancy?"
-
The Collaborative Group on Epidemiological Studies of Cervical Cancer has combined and reanalyzed any relevant data from all epidemiological studies on the association between cervical carcinoma and the pattern of oral contraceptive use.
-
In the November 20th issue of the Journal of Clinical Oncology, two important articles appear, demonstrating the clinical impact of a novel therapeutic, bevacizumab, in women with recurrent ovarian cancer.
-
In this issue: FDA warnings for existing drugs dominate pharmaceutical news this month.
-
-
Neither antibiotics nor nasal steroids nor the combination of the two reduces the duration of acute sinusitis symptoms compared with placebo.
-
IV bisphosphonate treatment is associated with an increased risk of inflammation in the bones of the jaw and face.
-
Although pancreatic cancer growth is considered rapid, early recognition of resectable disease remains the best chance for long-term survival. It is possible that an early sign of evolving pancreatic neoplasm is glucose intolerance. In a series of 30 pancreatic cancer patients evaluated at the Mayo Clinic, CT scans obtained 6 months or more before the diagnosis revealed potentially resectable lesions in some, and this was notably true for those who had CT scans and new-onset diabetes several months before the diagnosis of pancreatic cancer. Thus, physicians evaluating adults with newly diagnosed diabetes should consider the possibility that the glucose intolerance is an accompaniment of early pancreatic neoplasia.
-
Sorafenib has been approved by the FDA forthe treatment of inoperable hepatocellular cancer. It is an oral multikinase inhibitor that was previously approved for advanced renal cell carcinoma. It is manufactured by Bayer HealthCare AG in Germany and marketed by Bayer Pharmaceuticals Corporation as Nexavar.
-
Incidentalomas:It's All In Your Head, Skin Cancer Screening: Our Patients Want It!, and Bell's Palsy: Steroids, Acyclovir, Both, or Neither?
